Literature DB >> 29589987

Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement Summary of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update.

Gregory P Kalemkerian1, Navneet Narula1, Erin B Kennedy1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29589987     DOI： 10.1200/JOP.18.00035

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN： 1554-7477            Impact factor:   3.840


× No keyword cloud information.
  9 in total

1.  Broad-based genomic sequencing in advanced non-small cell lung cancer in the dock.

Authors:  Caterina Fumagalli; Elena Guerini-Rocco; Massimo Barberis
Journal:  Transl Lung Cancer Res       Date:  2019-12

Review 2.  Circulating Tumor DNA-Based Genomic Profiling Assays in Adult Solid Tumors for Precision Oncology: Recent Advancements and Future Challenges.

Authors:  Hiu Ting Chan; Yoon Ming Chin; Siew-Kee Low
Journal:  Cancers (Basel)       Date:  2022-07-04       Impact factor: 6.575

3.  Reflex ROS1 IHC Screening with FISH Confirmation for Advanced Non-Small Cell Lung Cancer-A Cost-Efficient Strategy in a Public Healthcare System.

Authors:  Maisam Makarem; Doreen A Ezeife; Adam C Smith; Janice J N Li; Jennifer H Law; Ming-Sound Tsao; Natasha B Leighl
Journal:  Curr Oncol       Date:  2021-08-25       Impact factor: 3.677

4.  Validity of Natural Language Processing for Ascertainment of EGFR and ALK Test Results in SEER Cases of Stage IV Non-Small-Cell Lung Cancer.

Authors:  Bernardo Haddock Lobo Goulart; Emily T Silgard; Christina S Baik; Aasthaa Bansal; Qin Sun; Eric B Durbin; Isaac Hands; Darshil Shah; Susanne M Arnold; Scott D Ramsey; Ramakanth Kavuluru; Stephen M Schwartz
Journal:  JCO Clin Cancer Inform       Date:  2019-05

5.  Crizotinib presented with promising efficacy but for concomitant mutation in next-generation sequencing-identified ROS1-rearranged non-small-cell lung cancer.

Authors:  Liang Zeng; Yizhi Li; Lili Xiao; Yi Xiong; Li Liu; Wenjuan Jiang; Jianfu Heng; Jingjing Qu; Nong Yang; Yongchang Zhang
Journal:  Onco Targets Ther       Date:  2018-10-15       Impact factor: 4.147

6.  Impact of Pre-Analytical Conditions on the Antigenicity of Lung Markers: ALK and MET.

Authors:  Rachel Miller; Trish Thorne-Nuzzo; Isabell Loftin; Abigail McElhinny; Penny Towne; June Clements
Journal:  Appl Immunohistochem Mol Morphol       Date:  2020 May/Jun

7.  A Novel Prognosis Signature Based on Ferroptosis-Related Gene DNA Methylation Data for Lung Squamous Cell Carcinoma.

Authors:  Xuequan Wang; Yinnan Meng; Changxin Liu; Haihua Yang; Suna Zhou
Journal:  J Oncol       Date:  2022-09-12       Impact factor: 4.501

8.  Impact of pulmonary interstitial lesions on efficacy and prognosis of EGFR-TKI-treated advanced non-small cell lung cancers.

Authors:  Xiang-Yan Zhang; Rui Cao; Yi-Jia Guo; Yan-Hua Zhen; Jia-He Zheng; Le-Tian Huang; Shu-Ling Zhang; Wei Jing; Li Sun; Jian-Zhu Zhao; Cheng-Bo Han; Jie-Tao Ma
Journal:  J Thorac Dis       Date:  2020-03       Impact factor: 3.005

9.  Comparison between Fluorimetry (Qubit) and Spectrophotometry (NanoDrop) in the Quantification of DNA and RNA Extracted from Frozen and FFPE Tissues from Lung Cancer Patients: A Real-World Use of Genomic Tests.

Authors:  Katsuhiro Masago; Shiro Fujita; Yuko Oya; Yusuke Takahashi; Hirokazu Matsushita; Eiichi Sasaki; Hiroaki Kuroda
Journal:  Medicina (Kaunas)       Date:  2021-12-17       Impact factor: 2.430
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.